Results 41 to 50 of about 66,588 (284)
Annals of Geriatric Medicine and Research, 2016 Background: Osteoporosis is commonly treated with bisphosphonates. These drugs promote osteoclast apoptosis, which suppresses bone resorption. However, the probability of side effects increases with long-term use of bisphosphonates.
Seo Young Lee +7 more
doaj +1 more source
Investigating the efficacy of bisphosphonates treatment against multiple myeloma induced bone disease using a computational model [PDF]
, 2014 Multiple myeloma (MM)-induced bone disease is mortal for most MM patients. Bisphosphonates are first-line treatment for MM-induced bone disease, since it can inhibit osteoclast activity and the resultant bone resorption by suppressing the differentiation
Fagan, Michael J. +3 more
core +1 more source
Non-bisphosphonate inhibitors of isoprenoid biosynthesis identified via computer-aided drug design. [PDF]
, 2011 The relaxed complex scheme, a virtual-screening methodology that accounts for protein receptor flexibility, was used to identify a low-micromolar, non-bisphosphonate inhibitor of farnesyl diphosphate synthase.
Cao, Rong +7 more
core +2 more sources
Association of oral bisphosphonates with cardioembolic ischemic stroke: a nested case-control study
Frontiers in Pharmacology, 2023 Background: Bisphosphonates have been reported to increase the risk of atrial fibrillation. Therefore, it is conceivable that they may increase the risk of cardioembolic ischemic stroke (IS).
Sara Rodríguez-Martín +11 more
doaj +1 more source
Bisphosphonate-related bilateral atypical femoral fractures : be aware and beware [PDF]
, 2011 Although bisphosphonates have a well established therapeutic role in the prevention of osteoporosis-related fractures, several reports published over the past 5-6 years suggest a possible causative relationship between long-term use of bisphosphonates ...
Cassar-Pullicino, Victor N. +2 more
core
Conservative Surgical Treatment of Bisphosphonate-Related Osteonecrosis of the Jaw with Er,Cr:YSGG Laser and Platelet-Rich Plasma: A Longitudinal Study [PDF]
, 2018 Introduction: The management of bisphosphonate-related osteonecrosis of the jaw (BRONJ), with no evidence-based guidelines, remains controversial. We aimed to evaluate the efficiency of a conservative surgical treatment combining Er,Cr:YSGG laser and ...
Albanese, Antonino +10 more
core +1 more source
Arthritis Care &Research, EarlyView.Objective We evaluated the role of 25‐hydroxyvitamin D (25[OH]D), prednisone, and other risk factors for bone mineral density (BMD) loss and osteoporosis in systemic lupus erythematosus (SLE). Methods We calculated the association between 25(OH)D levels and other potential risk factors and BMD measures (spine T scores) and osteoporosis (defined as a T ...
Nima Madanchi +4 more
wiley +1 more source
Bisphosphonate inhibits the expression of cyclin A2 at the transcriptional level in normal human oral keratinocytes. [PDF]
, 2017 Nitrogen-containing bisphosphonates (N-BPs) are the most widely used anti-resorptive agents in the treatment of bone-related diseases. N-BPs inhibit bone resorption by specifically targeting osteoclasts, bone-resorbing cells.
Kang, Mo K +5 more
core +1 more source
Advanced Healthcare Materials, EarlyView.This work introduces photo‐crosslinkable tyraminated poly(vinyl alcohol)‐gelatin (PVA‐GT) hydrogels as tunable injectable platforms for tissue engineering and growth factor delivery applications. This schematic illustrates the two developed hydrogel formulations and the experimental workflow used to evaluate their physico‐chemical properties in vitro ...
Alessia Longoni +15 more
wiley +1 more source
Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis: a meta-analysis
Journal of Orthopaedic Surgery and Research, 2018 Background The standard treatment for osteoporosis was controversial. Denosumab and bisphosphonates were two most common drugs. The purpose of this study was to compare the efficacy and safety of denosumab with bisphosphonates to treat osteoporosis ...
Jiaqi Wu +3 more
doaj +1 more source